
CLAIMS


~~1. An agent for treatment of dry eye, characterized by comprising a combination of a $P2Y_2$ receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, wherein the dosage form is an ophthalmic agent, wherein~~

~~the $P2Y_2$ receptor agonist is a compound represented by the following general formula [I] or a salt thereof:~~




~~[I]~~

~~[wherein X^1 represents a hydroxy group, a thiol group, a group represented by the following formula:~~




~~or a group represented by the following formula:~~



;


~~X^2 represents an oxygen atom, -NH- or $-CR^1R^2-$;~~

~~X^3 represents a group represented by the following formula:~~




;

5 ~~a group represented by the following formula:~~




~~or a group represented by the following formula:~~




;

~~A represents a group represented by the following formula:~~



or a group represented by the following formula:



;

Y represents CO, CS or $CHSR^6$;

R^1, R^2, R^3, R^4, R^5 and R^6 are the same as or different from one another and independently represent a hydrogen atom, a halogen atom or an alkyl group; and

n represents an integer of 0 to 4].


2. The agent for treatment of dry eye according to claim 1, wherein the $P2Y_2$ receptor agonist is P^1,P^4-bis(5'-uridyl)tetraphosphate, uridine 5'-triphosphate, adenosine 5'-triphosphate or a salt thereof.

3. The agent for treatment of dry eye according to claim 1 or 2, wherein the ophthalmic agent is an ophthalmic solution or an ophthalmic ointment.

14. An ophthalmic solution for treating dry eye, characterized by comprising a combination of P^1,P^4-bis(5'-uridyl)tetraphosphate or a salt thereof at a concentration of 1 to 5% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.05 to 0.5% (w/v).


25. An ophthalmic solution for treating dry eye, characterized by comprising a combination of P^1,P^4-bis(5'-uridyl)tetraphosphate or a salt thereof at a concentration of 3% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.1 to 0.5% (w/v).

~~6. A $P2Y_2$ receptor agonist and hyaluronic acid or a salt thereof for use in the treatment of dry eye by administering the $P2Y_2$ receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration in combination, wherein the dosage form is an ophthalmic agent, wherein the $P2Y_2$ receptor agonist is a compound represented by the following general formula [I] or a salt thereof:~~




~~[I]~~

~~[wherein X^1 represents a hydroxy group, a thiol group, a group represented by the following formula:~~




~~or a group represented by the following formula:~~



;


~~X^2 represents an oxygen atom, -NH- or $-CR^1R^2-$;~~

~~X^3 represents a group represented by the following formula:~~




;

~~a group represented by the following formula:~~




~~or a group represented by the following formula:~~




;

~~A represents a group represented by the following formula:~~



~~or a group represented by the following formula:~~



;

~~Y represents CO, CS or CHSR^{6};~~

~~R^{1}, R^{2}, R^{3}, R^{4}, R^{5} and R^{6} are the same as or different from one another and independently represent a hydrogen atom, a halogen atom or an alkyl group; and~~

~~n represents an integer of 0 to 4].~~


~~7. The P2Y$_2$ receptor agonist and hyaluronic acid or a salt thereof according to claim 6, wherein the P2Y$_2$ receptor agonist is P^{1},P^{4}-bis(5'-uridyl)tetraphosphate, uridine 5'-triphosphate, adenosine 5'-triphosphate or a salt thereof.~~

8. The $P2Y_2$ receptor agonist and hyaluronic acid or a salt thereof according to claim 6 or 7, wherein the ophthalmic agent is an ophthalmic solution or an ophthalmic ointment.

9. A $P2Y_2$ receptor agonist and hyaluronic acid or a salt thereof for use in the treatment of dry eye by administering P^1,P^4-bis(5'-uridyl)tetraphosphate or a salt thereof at a concentration of 1 to 5% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.05 to 0.5% (w/v) in combination, wherein the dosage form is an ophthalmic solution.


10. A $P2Y_2$ receptor agonist and hyaluronic acid or a salt thereof for use in the treatment of dry eye by administering P^1,P^4-bis(5'-uridyl)tetraphosphate or a salt thereof at a concentration of 3% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.1 to 0.5% (w/v) in combination, wherein the dosage form is an ophthalmic solution.

11. Use of a $P2Y_2$ receptor agonist and hyaluronic acid or a salt thereof for manufacturing an agent for treatment of dry eye comprising the $P2Y_2$ receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, wherein the treatment agent has a dosage form of an ophthalmic agent, wherein
the $P2Y_2$ receptor agonist is a compound represented by the following general formula [I] or a salt thereof:




[I]

~~[wherein X^1 represents a hydroxy group, a thiol group, a group represented by the following formula:~~




~~or a group represented by the following formula:~~



;


~~X^2 represents an oxygen atom, -NH- or $-CR^1R^2-$;~~

~~X^3 represents a group represented by the following formula:~~




;

~~a group represented by the following formula:~~




~~or a group represented by the following formula:~~




;

~~A represents a group represented by the following formula:~~



~~or a group represented by the following formula:~~



;

~~Y represents CO, CS or $CHSR^6$;~~

~~R^1, R^2, R^3, R^4, R^5 and R^6 are the same as or different from one another and independently represent a hydrogen atom, a halogen atom or an alkyl group; and~~

~~n represents an integer of 0 to 4].~~

~~12. The use according to claim 11, wherein the $P2Y_2$ receptor agonist is P^1,P^4-bis(5'-uridyl)tetraphosphate, uridine 5'-triphosphate, adenosine 5'-triphosphate or a salt thereof.~~

~~13. The use according to claim 11 or 12, wherein the ophthalmic agent is an ophthalmic solution or an ophthalmic ointment.~~

~~14. Use of P^1,P^4-bis(5'-uridyl)tetraphosphate or a salt thereof and hyaluronic acid or a salt thereof for manufacturing an agent for treatment of dry eye comprising P^1,P^4-bis(5'-uridyl)tetraphosphate or a salt thereof at a concentration of 1 to 5% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.05 to 0.5% (w/v).~~

~~15. Use of P^1,P^4-bis(5'-uridyl)tetraphosphate or a salt thereof and hyaluronic acid or a salt thereof for manufacturing an agent for treatment of dry eye comprising P^1,P^4-bis(5'-uridyl)tetraphosphate or a salt thereof at a concentration of 3% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.1 to 0.5% (w/v).~~